Childhood Leukaemias

Authored by , Reviewed by Dr Hayley Willacy | Last edited | Meets Patient’s editorial guidelines

This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Childhood Leukaemias article more useful, or one of our other health articles.

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Leukaemia is the most commonly diagnosed cancer in children, accounting for about 30% of all cases. The incidence peaks at age 3 years in boys and at 2 years in girls[1].

Of the different types of childhood leukaemia[1]:

  • Childhood leukaemia is a biologically diverse disease, arrived at by many different pathways.
  • Children with leukaemia (particularly ALL) have a range of different chromosomal and genetic abnormalities that defines subsets of the disease with prognostic relevance.
  • Common genetic lesions include:
    • Translocations to T-cell receptor (TCR) loci in T-lineage ALL.
    • Mutations of transcription factors regulating B-lineage development and cell maturation in B-lineage ALL (eg, PAX5, TCF3, EBF1).
    • Aberrational disruption of genes coding for transcription factors and coactivators in AML (eg, CBF).
    • BCR-ABL1 fusion and activation of multiple kinases in CML.

Leukaemia is the most commonly diagnosed cancer in children, accounting for about 30% of all cases[4].

Age distribution[1]

Leukaemia may affect children of any age but each type commonly affects a particular age group, as outlined below. This age clustering is thought by some to reflect the expression of particular cytogenetic aberrations at crucial stages of development:

  • ALL's peak incidence is in 2-3 year-olds.
  • AML's peak incidence in children is in those aged <2 years.
  • CML has two peaks of incidence in children aged <1 year and in early teenage years. The two peaks may reflect discrete disease entities.

Risk factors

  • Childhood leukaemia is more common in Caucasian children compared with those of Afro-Caribbean origin[5].
  • Boys are at slightly higher risk than girls.
  • A range of cytogenetic abnormalities has been found to be associated with an increased risk of the disease.
  • Genetic abnormalities such as Down's syndrome (increases risk by 10- to 20-fold).
    Fanconi's anaemia, ataxia telangiectasia and Bloom's syndrome are associated with an increased risk[6].
  • Significant exposure to ionising radiation and some chemicals is known to increase the risk of childhood leukaemia. Maternal abdominal X-ray during pregnancy increases the risk of childhood leukaemia.

Various common environmental exposures to electromagnetic radiation (eg, high-voltage power lines, mobile phone masts), low-level radionuclides from the nuclear power industry, and others, have been claimed as causative factors but have never been proven on epidemiological grounds.

Presentation is highly variable depending on the child's age and the extent of leukaemic infiltration of the bone marrow and other sites, as well as cytokine systemic effects:

  • The classical signs of anaemia, thrombocytopenia, hepatosplenomegaly or lymphadenopathy are highly suspicious of leukaemia but initial symptoms are often nonspecific and vague and are very similar to common, self-limiting viral illness[7].
  • The symptoms and signs listed below are common manifestations of the condition. There is no good evidence base to allow rational decision-making in primary care between phlebotomy and 'wait-and-see' approaches when symptoms are more vague[8]. Where symptoms are prolonged, particularly troublesome, or present atypically compared with more common illnesses in children, it may be wise to conduct initial investigations.
  • More rarely, acute leukaemia can present with life-threatening complications (see 'Complications', below) - do not delay admission for preliminary investigation of these children - refer directly to A&E or paediatric on-call teams[8].


  • General malaise, fatigue and lethargy.
  • Prolonged or recurrent episodes of fever.
  • Irritability and/or protracted crying.
  • Growth restriction and/or failure to thrive.
  • Shortness of breath and/or reduced exercise tolerance.
  • Dizziness and palpitations.
  • Bleeding diathesis, particularly causing epistaxis, bleeding gums and/or easy bruising.
  • Bone or joint pain, particularly in the legs.
  • Troublesome constipation.
  • Prolonged cough.
  • Headache.
  • Nausea and vomiting, particularly if central nervous system (CNS) infiltration is present.
  • Repeated or severe common childhood infections.


  • Pallor due to anaemia.
  • Signs of bleeding tendency such as petechiae, purpura, bruising, etc.
  • Signs related to severe infection.
  • Lymphadenopathy.
  • Hepatosplenomegaly.
  • Expiratory wheeze (due to mediastinal mass).
  • Cranial nerve lesions or other focal CNS pathology.
  • Testicular enlargement.

The overall differential diagnosis is very wide, depending on the mode of presentation and age of the child. Some of the more common conditions that may present similarly in clinical terms, or in their ability to cause abnormalities of the FBC that are akin to leukaemia, are listed below:





  • The most useful initial investigations in primary care are FBC and blood film. Typically, this shows pancytopenia due to bone marrow infiltration. Blasts may elevate the white cell count (despite neutropenia) and their presence on a peripheral smear is highly indicative of leukaemia.
  • However, the FBC will not always be abnormal in all cases of leukaemia, as some patients may not have marrow suppression. Similarly, peripheral blood films may be normal if blast cells are confined to the bone marrow.
    Any abnormal blood count or film in combination with suspicious clinical features should be referred urgently to a specialist centre[8].
  • Further investigations conducted in secondary care are likely to include:
    • Bone marrow aspiration and biopsy - for definitive diagnosis.
    • Imaging to determine the extent of the disease.
    • Immunophenotyping and cytogenetic analysis to enable risk stratification.
    • Lumbar puncture where there is suspected CNS infiltration.

Conventional cytogenetic analysis is an essential part of the multidisciplinary approach to the diagnosis, classification and risk-stratification of any person with acute leukaemia. The introduction of molecular-based cytogenetic techniques such as fluorescent in situ hybridisation (FISH) as an adjunct to conventional cytogenetics has improved the abnormality detection rate. The use of FISH led to the discovery of clinically relevant abnormalities that were previously unidentified and detected chromosomal abnormalities in samples that had previously failed cytogenetic analysis or where no abnormal clone had been detected[9]

There is increased incidence of leukaemia in children with:

  • Down's syndrome (15 x background incidence).
  • Fanconi's anaemia.
  • Ataxia telangiectasia.
  • Bloom's syndrome (a rare autosomal recessive condition associated with short stature and an increased risk of developing various cancers)[10]
  • The French-American-British (FAB) classification system is widely used in ALL but does not correlate with immunophenotypic and cytogenetic classifications. ALL is staged L1-L3 based upon morphological characteristics of blast cells.
  • There is no staging system for AML because by the time of diagnosis it has already spread throughout the bloodstream, and invariably invaded other body tissues. Patients are often grouped according to whether or not they have been treated for leukaemia previously.
  • CML is staged as being in the chronic, accelerated or blast phases depending upon disease activity, symptoms and the proportion of leukaemic cells that have undergone blast transformation.


  • Children with leukaemia and their families will require long-term help and support from various agencies, including the primary healthcare team.
  • A diagnosis of childhood leukaemia reverberates around the family and has implications for all, not just the child with the disease. Initial shock, anger and fear at diagnosis will transmute into potentially long stays in hospital and frequent outpatient visits. These may impact on educational continuity and social development, as well as parental attendance at work and presence at home. Siblings may feel neglected with the understandable shift of focus to the sick child.
  • Good communication between all of the many professionals involved in the child's care is critical.
  • Much of the treatment of leukaemia takes place in tertiary centres: there must be guidance to families and protocols at local secondary care hospitals as to how to recognise and manage complications that may arise following discharge after treatment, in particular febrile neutropenia.
  • Many families find it helpful to be put in contact with others who have been in the same situation, whose support and practical advice is often highly valued.
  • No routine immunisations during therapy and for six months afterwards[8].


    • ALL is always treated with high-intensity chemotherapy, usually via a central venous catheter (eg, Hickman lines). There are varying schedules depending on morphoimmunocytogenetic classification and extent of disease[8].
    • The inclusion of asparaginase in chemotherapy regimens to treat ALL has improved survival in children with ALL[11].
    • Allogenic bone marrow transplant is used to eliminate residual leukaemic cells in high-risk subtypes refractory to chemotherapy. Myeloablation (via total body irradiation and cyclophosphamide) is followed by the transplantation of allogenic haemopoietic stem cells. This treatment has significant morbidity and mortality associated with it due to infection and graft-versus-host disease.

  • AML (see also separate Acute Myeloid Leukaemia article):
    • AML is treated with intensive chemotherapy to destroy the leukaemic cell population as quickly as possible.
    • The child must then be supported through a period of intense marrow suppression until haematopoietic recovery occurs.
    • There is a broad range of abnormalities across different AML subtypes and further improvements in clinical outcome will require the development of targeted therapies for each subtype of disease[12].
    • It is considered to be very unlikely that further gains in long-term survival rates will be possible by just using more intense conventional chemotherapy[12].

  • CML (see also separate Chronic Myeloid Leukaemia article):
    • CML is treated very successfully with imatinib anti-tyrosine kinase therapy in adults and this is being evaluated in children.
    • Myeloablative hematopoietic stem cell transplantation from fully matched related and unrelated donors is the mainstay of long-term treatment.

Colony-stimulating factors are often used to promote haematopoietic function following chemotherapy. They have been proven to be effective in reducing hospital stay and risk of infections in children with ALL[13].


These may cause a life-threatening presentation of leukaemia:

  • Neutropenia - overwhelming sepsis (usually Gram-negative) +/- disseminated intravascular coagulation.
  • Thrombocytopenia - bleeding, pulmonary or gastrointestinal (GI) haemorrhage, stroke.
  • Electrolyte imbalance - hyperkalaemia and hyperphosphataemia (due to blast cell lysis).
  • Acute kidney injury (secondary to hyperuricaemia).
  • Acute airway obstruction (secondary to mediastinal thymic mass).
  • Leukostasis - stroke, acute pulmonary oedema, heart failure.
  • CNS involvement - stroke, seizures.

During treatment

  • Tumour lysis syndrome.
  • Renal or hepatic impairment.
  • Profound immunosuppression leading to sepsis (febrile neutropenia).
  • Thromboembolism.
  • Alopecia.
  • Mucositis causing severe mouth pain.
  • Hyperemesis.
  • GI erosion/bleeding.


  • Growth hormone deficiency and short stature (where cranial irradiation has been applied).
  • Neurological problems including headache, motor, co-ordination and cognitive impairment, seizures (again following cranial irradiation)[15].
  • Peripheral neuropathy (due to vincristine).
  • Obesity.
  • Congestive cardiac failure (due to toxicity of some chemotherapeutic agents - eg, doxorubicin).
  • Cognitive impairment.
  • Infertility[16].
  • Psychosocial impairment.
  • Second malignancy.

Although survival rates have improved dramatically over the past few decades, leukaemia remains one of the leading causes of death from disease in children[17].

  • Five-year survival rates for all types of childhood leukaemia rose from 33% to 79% between 1971 to 2000, as did cure rates (survival to point where no excess mortality), from 25% to 68% between 1971 and 1995[18].
  • Outlook in ALL is now good with an overall cure rate of 80%. Individual prognosis is highly dependent upon staging by the various classifications. Prognosis is best for children aged 1-10 years. Average time to cure has actually increased to 19 years for ALL, reflecting late relapse, secondary malignancies and treatment-related toxicity[18].
  • Prognosis has improved in AML with a five-year overall survival rate of 66% and an event-free survival rate of 56%. However, patients with adverse cytogenetic features or poor treatment response do badly even with allogenic bone marrow transplants and have a less than 20% cure rate[8].

It is hoped that the future will bring new therapies, targeting specific molecular defects and continued improvements individualising therapy, to maximise outcomes whilst minimising complications due to treatment.

Further reading and references

  1. Children's cancers incidence statistics; Cancer Research UK.

  2. Grigoropoulos NF, Petter R, Van 't Veer MB, et al; Leukaemia update. Part 1: diagnosis and management. BMJ. 2013 Mar 28346:f1660. doi: 10.1136/bmj.f1660.

  3. Kesy J, Januszkiewicz-Lewandowska D; Genes and childhood leukemia. Postepy Hig Med Dosw (Online). 2015 Mar 569:302-8. doi: 10.5604/17322693.1142719.

  4. Annesley CE, Brown P; Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol. 2015 Apr6(2):61-79. doi: 10.1177/2040620714565963.

  5. Leukemia: SEER Pediatric Monograph; US National Cancer Institute

  6. Seif AE; Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. Cancer Genet. 2011 May204(5):227-44. doi: 10.1016/j.cancergen.2011.04.005.

  7. Raab CP, Gartner JC Jr; Diagnosis of childhood cancer. Prim Care. 2009 Dec36(4):671-84. doi: 10.1016/j.pop.2009.07.002.

  8. Mitchell C, Hall G, Clarke RT; Acute leukaemia in children: diagnosis and management, BMJ 2009338:b2285

  9. Dixon-McIver A; Emerging technologies in paediatric leukaemia. Transl Pediatr. 2015 Apr4(2):116-24. doi: 10.3978/j.issn.2224-4336.2015.03.02.

  10. Sanz MM, German J; Bloom's Syndrome

  11. Boissel N, Sender LS; Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase. J Adolesc Young Adult Oncol. 2015 Sep4(3):118-28. doi: 10.1089/jayao.2015.0014.

  12. Rubnitz JE, Inaba H; Childhood acute myeloid leukaemia. Br J Haematol. 2012 Nov159(3):259-76. doi: 10.1111/bjh.12040. Epub 2012 Sep 12.

  13. Sasse EC, Sasse AD, Brandalise S, et al; Colony stimulating factors for prevention of myelosuppressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2005 Jul 20(3):CD004139.

  14. Long term follow up of survivors of childhood cancer; Scottish Intercollegiate Guidelines Network - SIGN (Mar 2013)

  15. Goldsby RE, Liu Q, Nathan PC, et al; Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2009 Nov 16.

  16. Grigoropoulos NF, Petter R, Van 't Veer MB, et al; Leukaemia update. Part 2: managing patients with leukaemia in the community. BMJ. 2013 Apr 9346:f1932. doi: 10.1136/bmj.f1932.

  17. Sun W, Gaynon PS, Sposto R, et al; Improving access to novel agents for childhood leukemia. Cancer. 2015 Jun 15121(12):1927-36. doi: 10.1002/cncr.29267. Epub 2015 Feb 11.

  18. Shah A, Stiller CA, Kenward MG, et al; Childhood leukaemia: long-term excess mortality and the proportion 'cured'. Br J Cancer. 2008 Jul 899(1):219-23.